COMP <GO>
BRVE vs TRAX // RSI-14 & 200D SMA MOMENTUM
Braveheart Bio Inc. (NASDAQ) VS. First Tracks Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BRVE 1
— TRAX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TRAX
LAST: $21.19 (-2.62%) • MKT CAP: $1.91B
rsi-technicals
49.2
LAST: $45.23 (-1.08%) • MKT CAP: $1.90B
rsi-technicals
65.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRVE VS. TRAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRVE | TRAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.53% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.2 | 65.8 | -16.59 | TRAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.91B | $1.90B | $7.7M | BRVE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRVE REV | TRAX REV | BRVE GROSS % | TRAX GROSS % | BRVE FCF | TRAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$143.0M |
| FY 2024 | — | $0 | — | — | — | -$126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRVE // BETA —
TRAX // BETA —